22-644 Phase I
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
Search Cancer Clinical Trials
Mass General Brigham Cancer Institute offers patients access to a wide variety of
clinical trials of promising new therapies. Use the search tool to find open protocols
for your type of cancer.
11 results
23-369 Phase I
A Phase 1b, Open-Label Study of Elranatamab in combination with Carzfilzomib plus Dexamethasone and Elranatmab in combination with PF-0790180 in Participants with relapsed refractory Multiple Myeloma
22-448 Phase II
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)
24-294 Phase II
A phase 2 multicenter study of the combination zanubrutinib, bendamustine, and rituximab in previously untreated Waldenström macroglobulinemia (ZEBRA Trial)
23-402 Phase II
A phase 2 study of elranatamab as consolidation after idecabtagene vicleucel in relapsed refractory multiple myeloma
24-727 Phase II
A phase 2 study of elranatamab in combination with isatuximab (ELISA) in relapsed and refractory multiple myeloma
24-044 Phase II
A Phase 2, Open-Label, Multicenter Study of BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
24-556 Phase III
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of anitocabtagene autoleucel (anito-cel) versus Standard of Care Therapy in Participants with Relapsed/Refractory Multiple Myeloma (iMMagine-3)
20-518 Phase I
A Phase I Clinical Trial with TriPRIL CAR T Cells for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
23-183 Phase II
A phase II study of ISABELA: isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
Showing 1 - 10 of 11 results